Nicotinell Med Peppermyntesmak (Nicotine)

Nicotinell Med Peppermyntesmak is a nicotine replacement therapy used in smoking cessation.

• Smoking cessation: assists adults in quitting tobacco by alleviating nicotine withdrawal symptoms.
• Nicotine dependence: provides controlled nicotine delivery to reduce cravings.
• Tobacco use disorder: supports reduction of tobacco consumption as part of a cessation program.

• Nicotine acts as an agonist at nicotinic acetylcholine receptors in the central nervous system, stimulating the release of dopamine and other neurotransmitters. This mimics the pharmacologic effects of cigarette‑derived nicotine, thereby decreasing withdrawal symptoms and cravings while the user gradually reduces dependence.

Common Side Effects

• Mouth irritation: mild soreness or tingling in the oral cavity.
• Hiccups: transient episodes after buccal placement.
• Nausea: occasional upset stomach.
• Throat irritation: dryness or scratchy feeling.
• Dizziness: light‑headed sensation.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Allergic reaction: rash, swelling, or difficulty breathing.
• Chest pain: unexpected discomfort in the chest area.
• Arrhythmia: irregular heart rhythm.
• Severe mouth ulceration: persistent lesions.
• Hypertension exacerbation: marked increase in blood pressure.
• Anaphylaxis: rapid onset of severe allergic response.

Before using Nicotinell Med Peppermyntesmak, consider the following precautions.

• Assess nicotine dependence: evaluate the level of addiction to tailor therapy.
• Cardiovascular disease: avoid or use with caution in recent myocardial infarction or unstable angina.
• Hypertension: monitor blood pressure regularly during treatment.
• Non‑smokers: product is not intended for individuals who do not use tobacco.
• Keep away from children: store out of reach to prevent accidental ingestion.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Nicotinell Med Peppermyntesmak may interact with other substances as follows.

Major Interactions (Avoid)

• Other nicotine‑containing products: concurrent use can lead to nicotine overdose.
• Strong CYP2A6 inhibitors (e.g., methoxsalen): may increase nicotine plasma levels.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: nicotine‑induced tachycardia may be masked.
• MAO‑inhibitors: potential for heightened blood pressure response.
• Caffeine: may intensify nervous system side effects.
• Antidepressants (SSRIs): monitor for increased anxiety or insomnia.